These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 32933141)

  • 1. Predicting Nonalcoholic Fatty Liver Disease through a Panel of Plasma Biomarkers and MicroRNAs in Female West Virginia Population.
    Pillai SS; Lakhani HV; Zehra M; Wang J; Dilip A; Puri N; O'Hanlon K; Sodhi K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease.
    Xu Q; Li Y; Shang YF; Wang HL; Yao MX
    World J Gastroenterol; 2015 Jan; 21(2):511-6. PubMed ID: 25593466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A micro-RNA expression signature for human NAFLD progression.
    Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
    J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.
    Auguet T; Aragonès G; Berlanga A; Guiu-Jurado E; Martí A; Martínez S; Sabench F; Hernández M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
    Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
    World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis.
    Sharma DL; Lakhani HV; Klug RL; Snoad B; El-Hamdani R; Shapiro JI; Sodhi K
    J Clin Cell Immunol; 2017 Oct; 8(5):. PubMed ID: 29177105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease.
    Kim TH; Lee Y; Lee YS; Gim JA; Ko E; Yim SY; Jung YK; Kang S; Kim MY; Kim H; Kim BH; Kim JH; Seo YS; Yim HJ; Yeon JE; Um SH; Byun KS
    Sci Rep; 2021 Jul; 11(1):14639. PubMed ID: 34282172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteocalcin and osteoprotegerin levels and their relationship with adipokines and proinflammatory cytokines in children with nonalcoholic fatty liver disease.
    El Amrousy D; El-Afify D
    Cytokine; 2020 Nov; 135():155215. PubMed ID: 32731119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
    Hochreuter MY; Dall M; Treebak JT; Barrès R
    Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.
    Latorre J; Moreno-Navarrete JM; Mercader JM; Sabater M; Rovira Ò; Gironès J; Ricart W; Fernández-Real JM; Ortega FJ
    Int J Obes (Lond); 2017 Apr; 41(4):620-630. PubMed ID: 28119530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Existence of a Strong Correlation of Biomarkers and miRNA in Females with Metabolic Syndrome and Obesity in a Population of West Virginia.
    Goguet-Rubio P; Klug RL; Sharma DL; Srikanthan K; Puri N; Lakhani VH; Nichols A; O'Hanlon KM; Abraham NG; Shapiro JI; Sodhi K
    Int J Med Sci; 2017; 14(6):543-553. PubMed ID: 28638270
    [No Abstract]   [Full Text] [Related]  

  • 15. Biomarkers in nonalcoholic fatty liver disease.
    Neuman MG; Cohen LB; Nanau RM
    Can J Gastroenterol Hepatol; 2014 Dec; 28(11):607-18. PubMed ID: 25575111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents.
    de Piano A; de Mello MT; Sanches Pde L; da Silva PL; Campos RM; Carnier J; Corgosinho F; Foschini D; Masquio DL; Tock L; Oyama LM; do Nascimento CM; Tufik S; Dâmaso AR
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1313-24. PubMed ID: 22932160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease.
    Pacifico L; Bezzi M; Lombardo CV; Romaggioli S; Ferraro F; Bascetta S; Chiesa C
    World J Gastroenterol; 2013 Jul; 19(25):4007-14. PubMed ID: 23840146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal miR-122, miR-128, miR-200, miR-298, and miR-342 as novel diagnostic biomarkers in NAFL/NASH: Impact of LPS/TLR-4/FoxO3 pathway.
    Samy AM; Kandeil MA; Sabry D; Abdel-Ghany AA; Mahmoud MO
    Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300631. PubMed ID: 38574101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
    Tan Y; Ge G; Pan T; Wen D; Gan J
    PLoS One; 2014; 9(8):e105192. PubMed ID: 25141008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease.
    Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Matono T; Kato J; Tokunaga S; Sugihara T; Hiramatsu A; Hyogo H; Tobita H; Sato S; Kawanaka M; Hara Y; Hino K; Chayama K; Murawaki Y; Isomoto H
    PLoS One; 2020; 15(2):e0219412. PubMed ID: 32106257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.